Since pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reaction are reported in human anti-PD-1/PD-L1 therapies9,38, these events should be assessed in future canine studies. This evidence concerns the gene CD274 and endocrine system disorder.